Overview A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients Status: Not yet recruiting Trial end date: 2022-03-31 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the safety and the effective doses of PDC-1421 in cancer patients with depression. Phase: Phase 1/Phase 2 Details Lead Sponsor: BioLite, Inc.